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Background: Cervical cancer is the second-most-common cause of malignancies in women worldwide, and the
oncogenic activity of the human papilloma virus types (HPV) E7 protein has a crucial role in anogenital tumors. In
this study, we have designed a therapeutic vaccine based on chitosan nanodelivery systems to deliver HPV-16 E7
DNA vaccine, considered as a tumor specific antigen for immunotherapy of HPV-associated cervical cancer. We have
developed a Nano-chitosan (NCS) as a carrier system for intramuscular administration using a recombinant DNA
vaccine expressing HPV-16 E7 (NCS-DNA E7 vaccine). NCS were characterized in vitro for their gene transfection
ability.
Results: The transfection of CS-pEGFP NPs was efficient in CHO cells and the expression of green fluorescent
proteins was well observed. In addition, NCS-DNA E7 vaccine induced the strongest E7-specific CD8+ T cell and
interferon γ responses in C57BL/6 mice. Mice vaccinated with NCS-DNA E7 vaccine were able to generate potent
protective and therapeutic antitumor effects against challenge with E7-expressing tumor cell line, TC-1.
Conclusions: The strong therapeutic effect induced by the Chitosan-based nanodelivery suggest that nanoparticles
may be an efficient carrier to improve the immunogenicity of DNA vaccination upon intramuscular administration and
the platform could be further exploited as a potential cancer vaccine candidate in humans.
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Cervical cancer is the most common cancer in women
worldwide and the leading cause of death from cancer
among women in the developing countries of the world
[1,2]. HPV-16 is the predominant etiologic agent of cer-
vical cancer and encodes three transforming oncogenes,
E5, E6, and E7. Their products are thus unique tumor
antigens and can be used as tumor vaccines [3]. Because
E6 and E7 oncoproteins are consistently retained and
expressed, the E6 and E7 oncoproteins represent natural
targets for anti-tumor immune response, and therefore
are considered tumor-associated antigens (TAA) [4].
Several approaches have been used to develop HPV
therapeutic vaccines including live vector, peptide/pro-
tein, DNA vaccine and whole cell-based approaches.* Correspondence: ghaem_amir@yahoo.com
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unless otherwise stated.These studies have shown the importance of T-cell re-
sponses in protecting against tumors in human and ani-
mal models [5]. Of these approaches, DNA vaccine
targeting the E7 antigen offers a potentially effective ap-
proach to control E7-expressing tumors [4,6,7].
DNA vaccines represent a valid approach to the gener-
ation of antigen-specific immunotherapy for several reasons
[8,9]. The plasmid vectors are safe, have low immunogen-
icity, and can be repeatedly administered. Additionally,
DNA vaccines can be easily prepared in large scale with
high purity and are highly stable compared to viral vectors
[10]. DNA vaccines have also demonstrated to generate
both humoral and cell mediated immune responses [11,12].
However, there are several drawbacks preventing the
clinical application of DNA vaccines [13]. After intra-
muscular administration, it is difficult for the vaccines to
move through cell membranes, so only a small amount
reaches antigen presenting cells (APC) to induce im-
mune responses [14,15].ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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cines in human subjects and non-human primates re-
main poorly understood [10], there is a clear need to
improve the transfection efficiency in vivo for allowing
much lower dose of plasmid DNA.
Novel delivery systems for administration may be keys
to address this need. Among possible delivery systems,
chitosan nanoparticles hold promise because of their
ability to protect encapsulated nucleic acid-based anti-
gens, and to promote delivery of adsorbed DNA to
antigen-presenting cells [13,16].
Chitosan (CS) is a non-toxic biodegradable and biocom-
patible polycationic polymer, which can bind and protect the
entrapped DNA from degradation by nuclease and increase
the efficiency of cellular DNA uptake [16-18], additionally
CS exhibit potential adjuvant properties, such as promoting
endocytotic uptake and elevating immune responses [19].
Zaharoff et al. have demonstrated that chitosan solu-
tion improved antigen-specific antibody and antigen-
specific splenic CD4+ proliferation responses to a sub-
cutaneous vaccination with a model protein antigen in
the absence of additional adjuvants [20]. These studies
established a basis for the use of chitosan nanoparticles
as a DNA vaccine delivery system.
In this study, we have evaluated the immune response
elicited in C57BL/6 mice by Nano-chitosan (NCS) con-
taining a recombinant DNA vaccine expressing HPV-16
E7, as well as the levels of protection against TC-1 tumor
cell challenge, following intramuscular administration.
Methods
Mice and cells
Female 6-8-week-old C57BL/6 mice were obtained from
the Institute Pasteur of Iran (Karaj, Iran). Mice were
housed for 1 week before the experiment, given free ac-
cess to food and water and maintained in a light/dark
cycle. All experiments were carried out in accordance
with the Animal care and use protocol of Golestan Uni-
versity of Medical Sciences of Iran.
The production and maintenance of TC-1 cells have
been described previously [12]. The cells were C57BL/6
mouse lung endothelial cells transformed with HPV 16
E6 and E7 oncogenes and an activated H-ras gene.
The in vitro transient transfection studies were performed
in Chinese hamster ovary (CHO) (Pasteur Institute of Iran)
cell line. The TC-1 and CHO cell lines were cultured in
RPMI 1640 medium (Gibco-BRL, UK) supplemented with
10% FBS (Gibco), 1 mM sodium pyruvate (Sigma), 100 U/ml
penicillin, and 100 μg/ml streptomycin, 0.4 mg/ml G418,
and 0.2 mg/ml hygromycin at pH 7.2 at 37°C with 5% CO2.
Plasmid construction
The generation of pcDNA3.1-E7 has been described pre-
viously. Plasmid constructs were confirmed by DNAsequencing and expression. Amplification and purifica-
tion of DNA were previously described [6]. Stocks of
endotoxin free DNA vaccine plasmids and vector control
plasmid (pcDNA3.1) in 0.1 M PBS were prepared for in-
vivo immunization studies using the EndoFree® Plasmid
Maxi Kit (Qiagen, Hilden, Germany) and dissolved in
endotoxin-free Tris-EDTA (Sigma, St. Louis, MO).
Preparation and characterization of nano-chitosan-based
DNA vaccine
Chitosan (CS) with the deacetylation degree of 95% and
the molecular weight (MW) of 360 kDa was purchased
from the Primex (Karmoy, Norway) and depolymerized
by a chemical reaction as previously described [21] to
obtain the low molecular weights of CS. The molecular
weight of depolymerized CS was determined by gel per-
meation chromatography (GPC) using pullulane stan-
dards [22]. The Nano-chitosan (NCS) were prepared
according to the ionotropic gelation method based on
the interaction between the negative groups of the pen-
tasodium tripolyphosphate (TPP) cross-linker (Merck,
Darmstadt Germany) and the positively charged amino
groups of NCS as described previously [23]. The com-
plexes were allowed to stand at room temperature for
30 min and stored at 4°C until use.
The hydrodynamic mean diameter of prepared chitosan
nanoparticles was determined by dynamic light scattering
using Nano-Zetasizer (Malvern Instruments, Worcestershire,
United Kingdom) with a wavelength of 633 nm at 25°C with
an angle detection of 90 degrees. The samples were diluted
with freshly filtered deionized water and all measurement
was done three times. The zeta potential of prepared
chitosan nanoparticles was determined by laser Doppler
electrophoresis using Zetasizer (Nano-ZS Malvern Instru-
ments). All samples were diluted (1:5) in deionized water
and each sample was measured three times.
NCS -DNA vaccine complex were prepared as previ-
ously described [24]. Briefly, the complex formation be-
tween NCS and pDNA at different N/P ratios were
analyzed by 0.8% agarose gel electrophoresis in TBE buf-
fer along with naked pDNA as control. Sample was ana-
lyzed using electrophoresis at 40 V for 60 min. The
in vitro transfection study was performed using CHO cell
line and pEGFP-N1 (Clontech Laboratories) as marker
gene. EGFP expression in cells investigated through fluo-
rescence microscopy. To evaluate the expression of NCS-
DNA vaccine encoding HPV-16 E7 gene (NCS-DNA E7)
in the CHO cells, SDS-PAGE and Western blot analysis
using monoclonal mouse anti-HPV E7 antibody were
used. Briefly, the extracted total proteins lysed in SDS-
PAGE sample loading buffer, and lysates separated by
SDS-PAGE. Separated proteins by SDS-PAGE, transferred
onto PVDF, and E7 protein was detected using anti-E7
monoclonal antibody (Abcam, UK). The specific band was
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St Louis, MO) and staining with diaminobenzidine (DAB)
substrate. The TC-1 cell line and cells transfected with
Lipofectamin were used as controls.Tumor therapy assay
For in vivo therapeutic experiments, C57BL/6 mice were
divided into six groups (n = 10). The mice were chal-
lenged by subcutaneous (S.C) injection in the right flank
with 2×105 TC-1 cells suspended in 100 μl PBS. After
one week, the mice were immunized intramuscularly
with 90 μg naked DNA vaccine encoding HPV-16 E7
(DNA-E7) thrice at 7-day intervals (group 1).
Each animal in Groups II and III were respectively ad-
ministered with 90 μg NCS-DNA E7 and NCS-pcDNA3.1
plasmid with the same protocol.
Blank Nano-chitosan (NCS), PBS and pcDNA3.1 were
injected according to the same protocol into the IV, V
and VI group of mice as control groups (NCS, PBS and
pcDNA3 groups).
Subcutaneous tumor volume was estimated according
to Carlsson’s formula [12]. Hence, the largest (a) and the
smallest (b) superficial diameters of the tumor were
measured in a blinded, coded fashion twice a week and
then the volume (V) of the tumor was calculated (V = a ×
b × b/2). Statistical analysis was performed using Student’s
t test. All values were expressed as means ± S.D.
Five mice per group were sacrificed one week follow-
ing the third immunization and the spleens were re-
moved aseptically, and then cell proliferation, cytolytic
activity and cytokine secretion were assayed. All tests
were performed in triplicate for each mouse. Results are
representative of three independent experiments.Lymphocyte proliferation assay (LPA)
One week after the third immunization, 5 mice per
group were sacrificed and their splenocytes were ob-
tained and treated with ammonium chloride-potassium
lysis buffer for 1 min to deplete erythrocytes. In 96-well
flat-bottom culture plates (Nunc, Denmark) splenocytes
(2 × 105 per well) were cultured in triplicate with RPMI-
1640 supplemented with 10% fetal calf serum, 1% L-glu-
tamine, 1% HEPES, 0.1% penicillin/streptomycin. The
cultured cells were incubated with 4 × 105 TC-1 cells
previously treated with mitomycin C (Sigma, St. Louis,
Mo) (30 μg/ml for 3 h), T cell mitogen PHA (phytohe-
magglutinin, positive control), 2 μg/ml of BSA (irrelevant
antigen), or medium (negative control) per well at 37°C
in 5% CO2.
After 3 days, MTT (3-(4,5-dimethyl tetrazolyl-2) 2,5
diphenyl) tetrazolyumbromide (Sigma chemicals) in con-
centration of 5 μg/ml was added per well and incubated
for 5 h at 37°C in 5% CO2. DMSO (dimethyl sulfoxide)(100 μl) was added to dissolve produced formazan
crystals.
Plates were read at 540 nm, and the results were
expressed as stimulation index (SI). The SI was deter-
mined as follows: OD values of stimulated cells minus
relative cell numbers of unstimulated cells divided by
relative OD values of unstimulated cells.
All tests were performed in triplicate for each mouse.
CD8 cytotoxicity assay
One week after the third immunization, for each sample
obtained from individual mouse (five mice per group),
single cell suspension of mononuclear cells (used as the
effecter cells) were cocultured in phenol red-free RPMI
containing 3% FCS with washed target cells EL4 at dif-
ferent effector-to-target cell (E/T) ratio (25:1, 50:1 and
100:1). For preparation of the target cells, EL-4 cells
were stimulated with 4 × 105 TC-1 cells previously treated
with mitomycin C (30 μg/ml for 3 h) and then incubated
for 4 h.
After centrifugation, the supernatants (50 μl/well)
were transferred to the 96-well flat-bottom plates, and
lyses of target cells were determined by measuring LDH
release using Cytotoxicity Detection Kit (LDH) accord-
ing to the procedures stated by the manufacturer
(Takara Company).
Several controls were used. The ‘high control’ was
used for measuring total LDH release from the target
cells (all EL4 cells were lysed with medium containing
1% Triton X-100). The ‘low control’ was used for meas-
uring natural release of LDH from the target cells (which
was obtained by adding EL4 cells only to the assay
medium).
The optical density was read at 490 nm after 30 min
incubation at room temperature and cytotoxicity was
calculated according to the formula:
% Cytotoxicity ¼ Experimental value − Low control =
High control − Low controlÞ  100
Cytokine assay
One week after third immunization, splenocytes were
obtained from five immunized mouse of each group and
used for the IFN-γ and IL-4 production assay. Briefly,
5 × 105 cells/well in the presence of 4 × 105 TC-1 cells
previously treated with mitomycin C (30 μg/ml for 3 h)
were harvested in 96-well flat-bottom plates with complete
RPMI 1640 supplement with 10% FCS, 1% L-glutamine,
1% HEPES, 0.1% 2-mercaptoethanol and 0.1% penicillin/
streptomycin. Cells were cultured for 2 days at 37°C in 5%
CO2. Supernatants were then collected and analyzed for
the presence of IFN-γ and IL-4 using ELISA commercial
kits according to the manufacturers protocol (eBioscience,
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for each mouse (Five mice per group).Statistical analysis
Lymphocyte proliferation, CTL and cytokine assay were
analyzed by a one-way ANOVA. Significant differences
of tumor growth on given days were assessed by Student’s
t-test. Differences were considered statistically significant
when P value <0.05. All tests were performed in triplicate
and all data are expressed as mean ± SD.Results
Characterization of chitosan-based nanodelivery systems
for E7 DNA vaccine
The particle size of the NCS ranged between 40 and
150 nm; nanoparticles showed a narrow size distribution
(PDI: 0.149), positive zeta potential with a mean diam-
eter of about 70 nm.
The mean zeta potential of prepared NPs before pack-
aging was approximately + 20 mV.
NCS/pDNA complexes were developed by adding the
pDNA solution to the prepared nanoparticle’s solution.
The complex formation was confirmed by gel electro-
phoresis [24].
The in vitro transfection study was performed using
CHO cell line and EGFP-N1 as marker gene through
fluorescence microscopy. EGFP expression was observed
in CHO cells transfected with NCS – pEGFP in a similar
extent to the control cells which were transfected with
lipofectamine (Figure 1A).Figure 1 Transfection analysis of the chitosan nanodelivery systems.
E7 antigen expression by NCS-DNA E7. Cell extracts or supernatants were prepare
gel electrophoresis, blotted on PVDF membranes, and incubated with the specifi
approximately 11 KDa of molecule weight. Lane 1: Lysate from TC-1 cells, Lane 2To evaluate the expression of HPV-16 E7 gene in the
CHO cells, Western blot analysis using monoclonal
mouse anti-HPV E7 antibody was used. The TC-1 cell
line and cells transfected with Lipofectamine were used
as positive controls. The analysis showed an expression
of HPV-16 E7 11 KDa from NCS-DNA E7 in the Western
blot according to the TC-1 cells and cells transfected with
Lipofectamine (Figure 1B).
Lymphocyte proliferation response to E7 antigen
One week after the third immunization, the splenocytes
from the immunized mice were harvested and re-
stimulated in vitro with E7 antigen for the lymphocyte
proliferation assay.
As shown in Figure 2, the lymphocyte proliferation
was significantly higher in mice treated with the NCS-
DNA E7 group than in those treated with DNA-E7 and
control groups (DNA-E7, NCS, NCS-pcDNA3.1, PBS and
pcDNA3.1) (P <0.001). As it appeared, there is no (statisti-
cally) significant difference among control groups.
Induction of antigen specific CD8+ CTL activity
In order to analyze the capacity of HPV-16 E7 to en-
hance the E7-specific CD8 + cytotoxic T-lymphocyte
(CTL) response, the response in immunized mice was
examined using the LDH release assay. The LDH release
increased with the E:T cell ratio up to the maximum
ratio of 100:1 used in the present study. As shown in
Figure 3, the cytolytic activity was significantly higher
in mice treated with the NCS-DNA E7, with almost
50% specific lysis at 100:1 E/T ratio, than in those inA) CHO cells transfected by NCS – pEGFP; B)Western blot analysis of HPV
d as described in Methods; proteins were separated by SDS polyacrylamide
c anti-HPV-16 E7 monoclonal antibody. The arrow indicates the E7 protein of
: pcDNA3.1/E7 with Lipofectamine, lane 3: NCS-DNA E7.
Figure 2 Splenocyte proliferation levels after in vitro stimulation with HPV-16 E7 antigen. The mice were injected intramuscularly thrice at
7-day intervals with different Nano-chitosan (NCS) regimes. One week after final immunization, spleens of individual mice (five per group) were
removed and lymphocyte proliferation was evaluated with MTT method. Formazan crystals were dissolved in dimethyl sulfoxide and optical
densities were read at 540 nm. Values are the mean ± standard error of the mean for the experiments. *** Indicates statistically significant
difference between the NCS-DNA E7 group as determined by one-way ANOVA (P < 0.001) with other groups.
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and pcDNA3.1) (P < 0.001). Furthermore, DNA-E7 (∼30%
at 100:1 E/T ratio), NCS-pcDNA3.1 (∼20% at 100:1 E/T
ratio) and NCS (∼17% at 100:1 E/T ratio) groups had a
significantly higher antigen-specific CTL response than
the group treated with PBS (P < 0.05).
Cytokine assay
We evaluated the E7-specific IFN-γ (representative of a
Th1 immune response) and IL-4 (representative of a
Th2 immune response) in splenocyte culture superna-
tants from mice vaccinated three times with DNA vac-
cine encoding HPV-16 E7 with or without chitosan
nanodelivery.
As shown in Figure 4A, B, mice immunized with the
NCS-DNA E7 produced significantly more IFN- γ and
IL-4 than other immunized mice (P < 0.001) and lym-
phocytes from the NCS-DNA E7 group produced the
largest amounts of IFN- γ and IL-4. Furthermore, the
DNA-E7 vaccine stimulated IFN- γ production more
than pcDNA3.1 and PBS groups (P < 0.05).
Reduction of tumor volume by therapeutic immunization
To determine whether the observed increase in E7-specific
immunity could be converted into a better E7-specific
therapeutic effect, we designed an in vivo tumor therapyexperiment via an E7-expressing murine tumor cell line,
TC-1, as a model of cervical carcinoma.
We investigated whether administration of NCS-DNA
E7 vaccine could lead to regression of preexisting tu-
mors. For this porpuse, TC-1 cells were first injected
into C57BL/6 mice at a dose of 2×105TC-1 cells in the
right flank. One week later, each mouse was immunized
with either NCS-DNA E7, E7 DNA, NCS, NCS-pcDNA3.1,
PBS and pcDNA3.1 thrice at 7-day intervals. The tumors
were measured twice a week once they became palpable.
The tumor volume was monitored up to 6 weeks after the
tumor challenge.
As shown in Figure 5, six weeks after tumor induction,
the final tumor volume were significantly reduced 52%
by NCS-DNA E7 (from 1.2 to 0.8 mm3) and 60% by E7
DNA (from 1.2 to 0.95 mm3) compared to pcDNA3 or
PBS control values (P < 0.001). Additionally, the average
tumor volume in the NCS-DNA E7 group was signifi-
cantly lower than that in the E7 DNA group (P < 0.01).
As control for nanodelivery, we also have evaluated
antitumor effects of NCS and NCS-pcDNA3.1. The sta-
tistical analysis of tumor volumes did not reveal signifi-
cant difference between these groups and PBS and
pcDNA3.1 groups (P > 0.05).
In summary, these results showed that chitosan-based
nanodelivery systems for E7 DNA vaccine could significantly
Figure 3 Analysis of the cytotoxic activity of CD8 induced by NCS-DNA E7 expressing the HPV-16 E7 antigen. CTL activity of the
lymphocytes from immunized mice (five mice per group) was measured at 100:1 E/T ratio by LDH release assay kit (Takara) as described in
Methods section. Specific lysis of target cells are shown with nonspecific background lysis subtracted. *** Indicates statistically significant
difference between NCS-DNA E7 group as determined by one-way ANOVA (P < 0.001) with other groups. ## shows the statistical significant
differences between DNA-E7, NCS-pcDNA3.1 and NCS treatments than the group treated with PBS (P < 0.01).
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expressing tumors. This indicated that chitosan-based
nanodelivery significantly promoted antitumor immunity
of DNA vaccine.
Discussion
Cancer immunotherapy using DNA vaccines have emerged
as a potentially promising approach for the control of tu-
mors. The main purpose of this study was to develop an
HPV-16 DNA vaccine that could express the E7 antigen
and enhance cellular immune response compared to the
naked DNA vaccine. With regard to the application of
DNA vaccines, if the delivery system can be directed to
APC and induce DNA vaccine release in endolysosomes,
an effective T-cell immunity may be achieved at lower
doses of plasmid DNA, which is safer and more cost-
effective [25].
Several studies have investigated the use of chitosan as
a gene delivery system, as it has shown rapid degrad-
ation in lysosomal compartment after cellular uptake,allowing for enhanced MHC-I restricted antigen presen-
tation [4]. In mice, DNA vaccines have been delivered
orally using a variety of carriers. One recent study has
shown that oral gene delivery with chitosan-DNA nano-
particles was able to generate a higher level expression
of gene in vivo [26].
Khatri et al. evaluated intranasal administration of chi-
tosan pDNA nanoparticles expressing the surface anti-
gen of hepatitis B virus (HBsAg) for immunization
against hepatitis B in Balb/c mice model demonstrating
successful generation of a systemic humoral and cellular
immune response [27].
In addition to the oral and intranasal vaccination
routes, chitosan-based systematic vaccine administration
routes such as subcutaneous and intramuscular have
also been explored for immunization. However, there are
very limited examples where chitosan has been applied
as DNA vaccine carriers for systemic vaccination.
Zaharoff et al. showed that chitosan dissolved in buffer
pH 6.2 could be used as an adjuvant to enhance both
Figure 4 Concentration of IFN-γ and IL-4 in supernatant following stimulation of cultured splenocytes with 4 × 105 TC-1 cells
previously treated with mitomycin C. Data presented as means ± standard error for five mice per group. *** Indicates statistically significant
difference (P < 0.001) between NCS-DNA E7 group as determined by one-way ANOVA (P < 0.01) with other groups (A, B). ## indicates the statistical
significant differences between DNA-E7 treatment and pcDNA3.1 and PBS groups (P < 0.01) (A).
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et al. evaluated a flu vaccine, formulated as a chitosan–
DNA nanoparticle complex. Intramuscular or intranasal
administration of the complex in BALB/c mice resulted inantibody titers that were elevated when compared to those
of naked DNA [16].
In present study, we have produced NCS of fewer than
100 nm diameter to facilitate the entrance of the particles
Figure 5 In vivo antitumor effects generated by treatment with NCS-DNA E7, DNA-E7, NCS-pcDNA3.1 and NCS. C57BL/6 mice were
inoculated with 2×105 TC-1 tumor cells subcutaneously. Mice were then treated with Nano-chitosan (NCS) and DNA regimes as described in
Methods. Mice were monitored for tumor growth by measuring diameters with calipers twice a week. Line and scatter plot graphs depicting the
tumor volume (in mm3) are presented. The data presented are a representation of three independent experiments.
Tahamtan et al. Journal of Biomedical Science 2014, 21:69 Page 8 of 10
http://www.jbiomedsci.com/content/21/1/69to the cells. The resultant NCS showed mean diameter
of about 70 nm with spherical shape and a narrow size
distribution. To evaluate the therapeutic efficacy of
chitosan-based nanodelivery systems in vivo, we inves-
tigate the efficiency of intramuscular administration of
encapsulated DNA vaccine in NCS, as carrier mole-
cules for HPV-16 DNA vaccine construct, carrying the
most immunogenic oncogenes of HPV-16 in mouse
model for cervical cancer (TC-1 cells). The results
demonstrated the induction of effective cellular im-
munity and antitumor response in immunized mice
and supported the feasibility of Nano-chitosan to be
explored for enhancing the immune responses of the
DNA vaccine.
In agreement with the results of the present study, it
has been previously shown that after intramuscular ad-
ministration of pVAX hepatitis B virus core (HBc) DNA-
nanoparticle complex as vaccine delivery systems in
C57BL/6 mice, a much stronger immune response was
elicited than for the vaccine alone, shown by elevated
antibody production, higher level of IFN-γ secretion,
and augmented Hbc Ag-specific cytotoxic T-lymphocyte
response in murine splenocytes [28].
Additionally, Zhao and colleagues have showed that chi-
tosan nanoparticles containing the DNA vaccine induced
significantly swine influenza -specific cell-mediated and
humoral immunity in mice [29].Moreover, present findings are in parallel with previ-
ous studies from Zhou et al. that investigated the potency
of the Chitosan as vectors for the delivery of plasmid
DNA. After delivery by intramuscular immunization in
BALB/c mice, the Chitosan induced an enhanced serum
antibody response 10 times more potent than naked
DNA vaccine. Additionally, in contrast to naked DNA,
the Chitosan induced potent cytotoxic T lymphocyte
responses at a low dose [30].
In other studies for evaluation of HPV-16 E7 as model
antigen in the development of a therapeutic DNA vac-
cine candidate, several DNA vaccines against human
papillomavirus (HPV) related malignancies have been
performed. Our previous findings demonstrated that
DNA vaccines encoding HPV-16 E7 could enhance the
induction of antigen-specific cytotoxic CD8+ T cell re-
sponses and IFN-γ and confer protective immunity and
therapeutic control of tumor growth [6,12]. In a trial for
anal dysplasia, encapsulated plasmid DNA encoding
HLA-A2 epitopes from HPV16 E7 protein in polymer
microparticles administrated intramuscularly and in-
duced enhanced T cell responses in 10 of 12 patients
[31]. Therefore, induction of both CD4+ T cells secret-
ing Th1-type cytokines and CD8+ cytotoxic T cells play
important effector roles for vaccines aiming therapeutic
activation of protective antitumor immunity, similar to
what was shown by the present NCS-DNA E7 vaccine.
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key role in supporting cellular uptake by cell–Chitosan
interactions and enhanced the antigen presentation.
Conclusions
Taken together, our study provides important insights for
eradicating HPV-induced cancers exploiting a Chitosan-
Based Nanodelivery. Through this new approach, the bio-
availability and stability of the vaccine were significantly
improved, leading to induction of antigen-specific CD8+
cytotoxic T lymphocytes (CTL), splenic CD4+. Ultimately,
the delivered vaccine induced production of IFN-γ to pro-
mote antitumor immunocytotoxic response and reduce
the tumor volumes.
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